Connect with us

Hi, what are you looking for?

Stock

Roche set to acquire Poseida Therapeutics for up to $1.5 billion

In a move within the biopharmaceutical industry, Roche has announced a definitive merger agreement to acquire Poseida Therapeutics. Poseida is known for its work in developing donor-derived CAR-T cell therapies, which are at the clinical stage.

Under the terms of the agreement, Roche will initiate a tender offer to purchase all outstanding shares of Poseida common stock. Shareholders of Poseida will receive $9.00 per share in cash upon the closing of the transaction. Additionally, they will be entitled to a non-tradeable contingent value right (CVR), which allows for potential milestone payments that could total up to $4.00 per share in cash.

The initial cash payment values Poseida’s equity at approximately $1.0 billion. When including the potential milestone payments, the total value of the deal could reach up to $1.5 billion.

The merger agreement has received unanimous approval from the boards of directors of both Roche and Poseida. This acquisition is poised to enhance Roche’s portfolio in the area of cell therapies, a field that is rapidly advancing and holds promise for treating various diseases.

The tender offer will provide Poseida’s shareholders with an immediate and certain cash value, while the CVR component of the agreement aligns the interests of both companies towards achieving future developmental milestones.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

This post appeared first on investing.com

    You May Also Like

    Investing

    In the days since President-elect Donald Trump won the presidential race, Nicole Bivens Collinson’s phone has barely stopped ringing. Collinson, who helps lead the...

    Investing

    Netflix’s cheaper, ad-supported tier has reached 70 million global monthly active users two years after it was launched. The company said Tuesday more than...

    Editor's Pick

    Adani Group shares experienced a rebound on Monday, recovering from last week’s steep losses sparked by U.S. criminal charges against Chairman Gautam Adani and...

    Stock

    Investing.com – Trip.com ADR (NASDAQ: TCOM) reported third quarter EPS of ¥7.05, ¥0.12 better than the analyst estimate of ¥6.93. Revenue for the quarter...



    Disclaimer: Techreportdiversity.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.


    Copyright © 2024 Techreportdiversity.com